The Department of Health of Abu Dhabi is advancing precision medicine for Alzheimer’s disease by incorporating APOE E4 genotyping into its pharmacogenomics (PGx) reports. This initiative, in collaboration with M42’s Biogenix Lab, aims to enhance treatment customization based on individual genetic profiles.

The updated PGx reports will enable healthcare providers to tailor treatments according to how patients metabolize medications, as well as the biochemical and physiological effects of drugs on their bodies. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH, emphasized that these insights can be integrated into treatment plans, particularly for therapies involving anti-amyloid monoclonal antibodies, ensuring safer and more effective care.

Patients carrying two copies of the APOE E4 gene may be at risk of severe side effects, including brain swelling or bleeding, when treated with anti-amyloid monoclonal antibodies. By identifying these genetic risks in advance, the updated PGx reports aim to support safer prescribing practices and provide more targeted care to patients diagnosed with Alzheimer’s disease.